Peritoneal metastases of rare carcinomas treated with cytoreductive surgery and HIPEC – A single center case series

Conclusion For patients with rare tumors, CRS and HIPEC is feasible with an acceptable perioperative morbidity and mortality. To improve knowledge in patient selection and outcome, rare tumors treated with CRS and HIPEC should be documented in central databases (as for example BIG RENAPE, Pierre-Benite, France).
Source: Annals of Medicine and Surgery - Category: General Medicine Source Type: research